 Home > Medical News > Latest Medical News > Positive results in clinical trial of bispecific antibody for treatment of refractory HER2-positive breast cancer

Positive results in clinical trial of bispecific antibody for treatment of refractory HER2-positive breast cancer

 Last Update: 2022-01-04
 Source: Internet
 Author: User

Tags

cathode positive negative

1 2 dichloropropane

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Zymeworks announced that its bispecific antibody Zanidatamab targeting HER2, combined with chemotherapy, has shown encouraging results in a phase 1 clinical trial for the treatment of refractory HER2-positive breast cancer patients who have received multiple pre-treatments.

Zanidatamab can simultaneously bind to two non-overlapping HER2 epitopes, which is called biparatopic binding

The results of the Zanidatamab clinical trial showed that the combination therapy achieved an objective response rate of 37.

Previously, the FDA has granted Zanidatamab a breakthrough therapy designation for use in previously treated HER2 gene amplified biliary tract cancer (BTC) patients, and has granted Zanidatamab two fast-track designations as a single-agent treatment for refractory BTC, and Combined with chemotherapy in the first-line treatment of gastroesophageal adenocarcinoma

In addition, Zanidatamab has been approved by the FDA as an orphan drug for the treatment of biliary tract cancer, gastric cancer and ovarian cancer, and has been approved by the European Medicines Agency as an orphan drug for the treatment of biliary tract cancer and gastric cancer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.